US Drug Recall Register

FDA Drug Recalls

14,801 recalls, newest first

Class II · Moderate risk Terminated

Urolet Mb Urinary Antiseptic

Reason CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures

Burel Pharmaceuticals Inc NDC 35573-302-30 D-0156-2017
Class II · Moderate risk Terminated

Hyolev MB URINARY ANTISEPTIC Tablets

Reason CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures

Burel Pharmaceuticals Inc NDC 35573-301-90 D-0155-2017
Class II · Moderate risk Terminated

Sodium Chloride Ophthalmic Solution

Reason Subpotent Drug: concentration of product is less than labeled amount.

Akorn Inc NDC 17478-623-12 D-0124-2017
Class III · Low risk Terminated

FIRST Omeprazole 2mg/mL in FIRST PPI Suspension Compounding Kit

Reason Labeling: Label error on declared strength. Package Insert -Error in the Description section of the package insert refers to the strength as 3mg per mL; however it should state 2mg per mL

CutisPharma, Inc. NDC 65628-070-03 D-0139-2017
Class III · Low risk Terminated

FIRST Omeprazole 2mg/mL in FIRST PPI Suspension Compounding Kit

Reason Labeling: Label error on declared strength. Package Insert -Error in the Description section of the package insert refers to the strength as 3mg per mL; however it should state 2mg per mL

CutisPharma, Inc. NDC 65628-070-05 D-0138-2017
Class II · Moderate risk Terminated

Duloxetine Delayed-release Capsules USP 30 mg 30-count bottles

Reason Failed Tablet/Capsule Specifications: Capsule shell (s) opening inside the bottle The Initial reports stated one or two capsules in a bottle count of 30s opening. First report came in June 14, 2016. Till date about 22 reports have come in from pharmacies which report two batches 130/16/001 and 130/16/002. Third batch 130/16/003 is not distributed yet, will be recalled from warehouse.

Inventia Healthcare Private Limited NDC 69097-298-02 D-0224-2017
Class III · Low risk Terminated

Ceftriaxone for Injection

Reason Labeling: Missing Label

Sandoz Inc NDC 0409-7332-01 D-0145-2017
Class III · Low risk Terminated

Invokamet

Reason Labeling: Incorrect or Missing Package Insert - Xarelto prescribing information outserts may be affixed to the exterior of Invokamet bottles in place of the Invokamet prescribing information outsert.

Janssen Ortho L.L.C. NDC 50458-543-60 D-0115-2017
Class III · Low risk Terminated

Zeasorb AF

Reason Labeling Not Elsewhere Classified: front labels have the incorrect NDC or 0145-1506-01 instead of the correct NDC of 0145-1506-05 and some back labels have the incorrect indication stating "use for the cure of most jock itch" rather than "use for the cure of most athlete's foot".

GSK Consumer Healthcare NDC 0145-1506-01 D-0142-2017
Class III · Low risk Terminated

Olanzapine tablets

Reason Failed impurities/degradation specifications: due to out-of-specification result for the Related Substance Compound C (Impurity 6 - N-Oxide at the 18 month stability station.

Dr. Reddy's Laboratories, Inc. NDC 55111-163-30 D-0468-2017
Class III · Low risk Terminated

AHP NIFEdipine Capsules

Reason Presence of Foreign Tablets/Capsules

Amerisource Health Services D-0144-2017
Class III · Low risk Terminated

HCG-Vitamin B12 5000 IU-8 mg in 10 mL vial

Reason Labeling; Error on Declared Strength; product description incorrectly states HCG 7500 units instead of 5000 units. The primary panel is correct

Pharm D Solutions, LLC D-0427-2017
Class III · Low risk Terminated

Testosterone Cypionate 200 mg/mL in Sesame Oil

Reason Incorrect/Undeclared Excipient; product description section of testosterone cypionate incorrectly states "in grapeseed oil" instead of "in sesame oil" . The primary panel is correct

Pharm D Solutions, LLC D-0426-2017
Class II · Moderate risk Terminated

Succinylcholine Chloride

Reason Lack of Assurance of Sterility: A portion of the batch quantity was compounded outside of the firm's process media validation.

Pharmedium Services, LLC NDC 61553-0364-65 D-0125-2017
Class III · Low risk Terminated

NIFEdipine Capsules USP

Reason Presence of Foreign Tablets/Capsules

Actavis Elizabeth LLC NDC 0228-2407-10 D-0143-2017
Class II · Moderate risk Terminated

DIPYRIDAMOLE Tablets USP

Reason Presence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 100-count bottle and 50 mg Persantine tablet was found in a 100 count bottle of 75 mg Dipyridamole.

Boehringer Ingelheim Pharmaceuticals, Inc. NDC 0054-0436-25 D-0114-2017
Class II · Moderate risk Terminated

Persantine

Reason Presence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 100-count bottle and 50 mg Persantine tablet was found in a 100 count bottle of 75 mg Dipyridamole.

Boehringer Ingelheim Pharmaceuticals, Inc. NDC 0597-0019-01 D-0113-2017
Class II · Moderate risk Terminated

Travoprost Ophthalmic Solution USP

Reason Lack of Assurance of Sterility; damage to the internal portion of the dropper tip portion of the container

Par Pharmaceutical, Inc. D-0154-2017
Class II · Moderate risk Terminated

Phenobarbital Tablets

Reason Failed Dissolution Specifications: Phenobarbital Tablets have an out of specification for dissolution at the 12 month stability time point

West-Ward Pharmaceuticals Corp. NDC 0143-1455-01 D-1045-2017
Class II · Moderate risk Terminated

PredniSONE Tablets USP

Reason Failed Tablet/Capsule Specifications: Discovery of an underweight tablet.

West-Ward Pharmaceutical NDC 0054-4741-25 D-0008-2017
Class III · Low risk Terminated

Paricalcitol Capsules

Reason Failed Impurities/Degradation Specifications: This repackaged product was recalled by its manufacturer due to failed results for impurities.

Amerisource Health Services NDC 60687-106-25 D-0009-2017
Class III · Low risk Terminated

Clonazepam Tablets

Reason Failed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 16 month timepoint.

Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-882-20 D-0136-2017
Class III · Low risk Terminated

Clonazepam Tablets

Reason Failed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 15 month timepoint.

Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-881-20 D-0135-2017
Class II · Moderate risk Terminated

USCG Boat Response Kit - Product Code 80-0353

Reason Lack of Assurance of Sterility: Concerns with product sterility by the manufacturer of the eye wash irrigating solution.

North American Rescue LLC. D-0183-2017